EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?

Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis-Alexios Koumprentziotis, Konstantinos Karampinos, Konstantinos Drougkas, Ioannis Karavolias, Elias Kotteas

Clinical Breast Cancer · 2024

DOI: 10.1016/j.clbc.2024.01.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Ioanna Ploumaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Αthens, Greece. Electronic addre…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleNeoadjuvant TherapyCyclin-Dependent Kinase 4Molecular Targeted TherapyProtein Kinase InhibitorsCyclin-Dependent Kinase 6Antineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

AbemaciclibCDK 4/6 inhibitorsHR+/HER2−PalbociclibRibociclib

Substanzen

Cyclin-Dependent Kinase 4Protein Kinase InhibitorsCyclin-Dependent Kinase 6

Autor:innen und Institutionen

  • Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Αthens, Greece. Electronic address: ioannaploum@gmail.com.
  • Oncology Unit, 3rd Department of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Αthens, Greece.

Zitieren

APA

Ploumaki, I., Triantafyllou, E., Koumprentziotis, I. A., Karampinos, K., Drougkas, K., Karavolias, I., & Kotteas, E. (2024). Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.01.002

Vancouver

Ploumaki I, Triantafyllou E, Koumprentziotis IA, Karampinos K, Drougkas K, Karavolias I, et al. Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.01.002

BibTeX
@article{Ploumaki2024,
  author = {Ploumaki, Ioanna and Triantafyllou, Efthymios and Koumprentziotis, Ioannis-Alexios and Karampinos, Konstantinos and Drougkas, Konstantinos and Karavolias, Ioannis and Kotteas, Elias},
  title = {Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?},
  journal = {Clinical Breast Cancer},
  year = {2024},
  doi = {10.1016/j.clbc.2024.01.002}
}
Kostenlos starten →